A method based on a redundantly designed combination of data for indicating a presence or non-presence of aggressive prostate cancer (PCa) in an individual, comprising the steps of: 1. Providing at least one biological sample from said individual; 2. In said biological sample, analyzing a. a category of PCa biomarkers, by measuring a presence or concentration of at least three kallikrein-like PCa biomarkers; and b. a category of SNPs related to PCa (SNPpc), by measuring a presence or absence of one or two risk allele(s) of each of a plurality of SNPpc of said category of SNPpc; 3. Combining data regarding at least three kallikrein-like PCa biomarkers, to form a biomarker composite value representing the PCa biomarker-related risk of developing PCa, wherein the method allows disregarding data of a subset of at least one of said PCa biomarkers, such as one or two of said PCa biomarkers, when forming said biomarker composite value of at least three PCa biomarkers; 4. Combining data regarding said category of SNPpc, to form a SNPpc composite value representing the SNPpc-related risk of developing PCa, wherein the method allows disregarding data of a subset of from about 10% to 30%, such as 15%, 20% or 30%, of the SNPpc of the SNPpc category when forming the SNPpc composite value, wherein said SNPpc composite value is formed from at least 70 SNPpc selected from any of the SNPpc of Table I or Table II; 5. Combining the biomarker composite value and the SNPpc composite value, to form an overall composite value; 6. Correlating said overall composite value to the presence or non-presence of aggressive PCa in said individual by comparing said overall composite value to a pre-determined cut-off value established with control samples of known presence of aggressive PCa, and non-presence of aggressive PCa, wherein at least one, such as two, of the kallikrein-like PCa biomarkers is selected from the group consisting of (i) PSA, (ii) total PSA (tPSA), (iii) intact PSA (iPSA), (iv) free PSA (fPSA), and (v) hK2. 1. Providing at least one biological sample from said individual; 2. In said biological sample, analyzing a. a category of PCa biomarkers, by measuring a presence or concentration of at least three kallikrein-like PCa biomarkers; and b. a category of SNPs related to PCa (SNPpc), by measuring a presence or absence of one or two risk allele(s) of each of a plurality of SNPpc of said category of SNPpc; a. a category of PCa biomarkers, by measuring a presence or concentration of at least three kallikrein-like PCa biomarkers; and b. a category of SNPs related to PCa (SNPpc), by measuring a presence or absence of one or two risk allele(s) of each of a plurality of SNPpc of said category of SNPpc; 3. Combining data regarding at least three kallikrein-like PCa biomarkers, to form a biomarker composite value representing the PCa biomarker-related risk of developing PCa, wherein the method allows disregarding data of a subset of at least one of said PCa biomarkers, such as one or two of said PCa biomarkers, when forming said biomarker composite value of at least three PCa biomarkers; 4. Combining data regarding said category of SNPpc, to form a SNPpc composite value representing the SNPpc-related risk of developing PCa, wherein the method allows disregarding data of a subset of from about 10% to 30%, such as 15%, 20% or 30%, of the SNPpc of the SNPpc category when forming the SNPpc composite value, wherein said SNPpc composite value is formed from at least 70 SNPpc selected from any of the SNPpc of Table I or Table II; 5. Combining the biomarker composite value and the SNPpc composite value, to form an overall composite value; 6. Correlating said overall composite value to the presence or non-presence of aggressive PCa in said individual by comparing said overall composite value to a pre-determined cut-off value established with control samples of known presence of aggressive PCa, and non-presence of aggressive PCa, wherein at least one, such as two, of the kallikrein-like PCa biomarkers is selected from the group consisting of (i) PSA, (ii) total PSA (tPSA), (iii) intact PSA (iPSA), (iv) free PSA (fPSA), and (v) hK2.